Received Jun 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | N4935 | — |
Boostrix - Administration after temperature excursion; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number N4935 with expiry date 19-MAY-2028) for prophylaxis. On 03-JUN-2026, the patient received Boostrix .5 ml. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Boostrix - Administration after temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-JUN-2026 A nurse called to ask for information about the stability of Boostrix, Engerix-B, Havrix, Fluarix, Kinrix, Menveo (1 vial), Bexsero vaccines exposed to -0.9 degree Celcius. Vaccines were out of range for 7h 1min. The nurse mentioned that morning, a patient received Boostrix vaccine before realizing that the vaccine was exposed to a temperature below the recommended range. No symptomatic events were reported.